Axim Biotechnologies Inc (AXIM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2024, filed Aug 19, 2024. Each column of the statement tables below links to the filing it was taken from.
Axim Biotechnologies Inc (AXIM) reported $40K in revenue for fiscal year 2023, up 345.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business operates through external financing while an asset-light structure leaves liquidity structurally thin against mounting obligations.
Operating cash flow matched free cash flow at-$1.03M while capital expenditures were zero, so cash needs came from ongoing operations rather than expansion. Financing cash flow of$1.14M nearly offset that outflow, yet total liabilities reached$11.8M in FY2023, indicating the balance sheet depends on funding inflows while obligations accumulate.
At FY2023, current assets were
Net loss was
Financial Health Signals
Axim Biotechnologies Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Axim Biotechnologies Inc scores -28.34, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.3M) relative to total liabilities ($11.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Axim Biotechnologies Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Axim Biotechnologies Inc reported a net loss of $8.1M while operations used $1.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Axim Biotechnologies Inc reported an operating loss of $2.8M against $140K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Axim Biotechnologies Inc generated $17K in revenue in Q2 2024. This represents an increase of 76.0% from the same quarter a year earlier. Against the prior quarter it is down 67.0%.
Axim Biotechnologies Inc's EBITDA was -$461K in Q2 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.9% from the same quarter a year earlier. Against the prior quarter it is down 57.1%.
Axim Biotechnologies Inc reported -$2.3M in net income in Q2 2024. This represents an increase of 39.0% from the same quarter a year earlier. Against the prior quarter it is down 676.5%.
Axim Biotechnologies Inc earned -$0.01 per diluted share (EPS) in Q2 2024. This represents an increase of 50.0% from the same quarter a year earlier. Against the prior quarter it is down 900.0%.
Cash & Balance Sheet
Axim Biotechnologies Inc held $6K in cash against $94K in long-term debt as of Q2 2024, with $6.6M of liabilities due within a year.
Not reported for Q2 2024.
Not reported for Q2 2024.
Margins & Returns
Axim Biotechnologies Inc's gross margin was 90.0% in Q2 2024, indicating the percentage of revenue retained after direct costs. This is down 10.0 percentage points from the same quarter a year earlier.
Not shown for Q2 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2024.
Capital Allocation
Axim Biotechnologies Inc invested $4K in research and development in Q2 2024. This represents a decrease of 88.1% from the same quarter a year earlier. Against the prior quarter it is down 73.8%.
Not reported for Q2 2024.
Not reported for Q2 2024.
AXIM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17K+76.0% | $53K+616.2% | $13K | $10K+629.1% | $10K | $7K | N/A | $1K-83.8% |
| Cost of Revenue | $2K | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Gross Profit | $16K+58.5% | N/A | N/A | N/A | $10K | N/A | N/A | $1K-83.8% |
| R&D Expenses | $4K-88.1% | $15K-23.8% | $36K | $35K+16.8% | $34K-3.1% | $20K-54.0% | N/A | $30K-55.8% |
| SG&A Expenses | $473K-16.6% | $331K-44.0% | $623K | $457K-61.4% | $567K-38.3% | $591K-39.8% | N/A | $1.2M-53.1% |
| Operating Income | -$569K+18.4% | -$402K+43.5% | -$754K | -$589K+55.3% | -$698K+34.2% | -$711K+37.3% | N/A | -$1.3M+59.8% |
| EBITDA | -$461K+21.9% | -$294K+51.4% | -$647K | -$482K+60.2% | -$591K+38.0% | -$604K+41.2% | N/A | -$1.2M+63.0% |
| Interest Expense | $178K-76.3% | -$164K-182.8% | -$618K | $65K+12.5% | $752K+1148.8% | -$58K-103.8% | N/A | $57K+2.6% |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$2.3M+39.0% | -$292K+89.4% | -$1.9M | $328K+116.1% | -$3.7M-204.5% | -$2.8M-32.4% | N/A | -$2.0M+38.2% |
| EPS (Basic) | -$0.01+50.0% | $0.00+92.3% | -$0.01-116.7% | $0.00+108.3% | -$0.02-100.0% | -$0.01-30.0% | -$0.01+90.0% | -$0.01+60.0% |
| EPS (Diluted) | -$0.01+50.0% | $0.00+92.3% | -$0.01-116.7% | $0.00 | -$0.02 | -$0.01-30.0% | -$0.01+90.0% | -$0.01 |
| Diluted Shares (Avg) | N/A | N/A | N/A | 479M | 226M | N/A | N/A | N/A |
AXIM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.7M-12.2% | $3.9M-2.7% | $4.1M-2.1% | $4.0M-9.7% | $4.2M-6.1% | $4.0M-20.2% | $4.2M-20.9% | $4.5M-68.6% |
| Current Assets | $20K-79.2% | $97K+71.0% | $156K+50.5% | $23K-90.7% | $97K-43.7% | $57K-88.6% | $104K-83.7% | $249K-50.2% |
| Cash & Equivalents | $6K-93.8% | $97K+80.6% | $156K+230.9% | $23K-85.8% | $97K+49.6% | $54K-86.9% | $47K-89.6% | $164K-51.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $20K-0.2% |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $13.3M-5.2% | $11.4M+11.6% | $11.8M+30.3% | $10.0M+12.9% | $14.0M+69.6% | $10.2M+20.2% | $9.0M+18.0% | $8.9M-7.7% |
| Current Liabilities | $6.6M-21.4% | $4.8M-1.2% | $6.0M+76.2% | $4.3M+35.2% | $8.4M+208.5% | $4.9M+44.7% | $3.4M+31.4% | $3.2M+98.3% |
| Non-Current Liabilities | $6.7M+18.8% | $6.6M+23.2% | $5.8M+2.7% | $5.7M+0.4% | $5.6M+1.6% | $5.3M+4.2% | $5.6M+11.1% | $5.7M-28.9% |
| Long-Term Debt | $94K | $118K | $137K | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$9.5M+2.2% | -$7.4M-20.9% | -$7.7M-58.7% | -$6.0M-35.9% | -$9.8M-161.2% | -$6.2M-80.0% | -$4.8M-106.4% | -$4.4M-194.2% |
| Retained Earnings | -$74.7M-5.9% | -$72.5M-8.4% | -$72.2M-12.6% | -$70.3M-11.2% | -$70.6M-15.4% | -$66.9M-11.5% | -$64.1M-10.8% | -$63.2M-26.9% |
Not reported in any period shown, so not listed: Goodwill.
AXIM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$262K+59.4% | -$253K-77.9% | $20K+106.2% | -$265K+17.7% | -$644K+8.6% | -$142K+79.8% | -$316K+60.2% | -$321K+39.7% |
| Depreciation & Amortization | $108K+1.3% | $108K+1.2% | $107K-0.1% | $107K0.0% | $107K+0.7% | $107K+0.2% | $107K-94.9% | $107K+1439.2% |
| Stock-Based Compensation | $10K-55.1% | $10K-90.7% | N/A | $38K-92.6% | $21K-88.3% | $104K-45.0% | N/A | $517K-32.1% |
| Capital Expenditures | N/A | $3K | $0 | N/A | N/A | N/A | $0-100.0% | $3K |
| Free Cash Flow | N/A | -$255K | $20K+106.2% | N/A | N/A | N/A | -$316K+61.2% | -$324K |
| Investing Cash Flow | $0 | -$3K | $0 | $0+100.0% | $0+100.0% | $0 | $0+100.0% | -$3K+72.9% |
| Financing Cash Flow | $171K-75.1% | $196K+32.0% | $114K-42.9% | $190K-55.0% | $688K+87.3% | $148K-77.5% | $199K-78.6% | $423K-37.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AXIM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.0%-10.0pp | N/A | N/A | N/A | 100.0% | N/A | N/A | 100.0%0.0pp |
| Operating Margin | -3257.9% | -758.0% | -5978.4% | -6142.7% | -7027.2% | -9607.1% | N/A | -100298.3% |
| Net Margin | -12985.9% | -551.7% | -15083.9% | 3428.3% | -37499.2% | -37347.9% | N/A | -154836.1% |
| Return on Assets | -60.9%+26.8pp | -7.4%+60.9pp | -46.2% | 8.1%+53.5pp | -87.7%-60.6pp | -68.3%-27.1pp | N/A | -45.4%-22.3pp |
| Current Ratio | 0.000.0x | 0.020.0x | 0.030.0x | 0.01-0.1x | 0.01-0.1x | 0.01-0.1x | 0.03-0.2x | 0.08-0.2x |
| Asset Turnover | 0.000.0x | 0.010.0x | 0.00 | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x |
| FCF Margin | N/A | -482.0% | 155.1% | N/A | N/A | N/A | N/A | -24652.6% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$7.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Axim Biotechnologies Inc AXIM | FY2023 | $40K | -$8.1M | N/A | $1.3M | — |
| Vaccinex Inc VCNX | FY2024 | $601K | N/A | N/A | $2.8M | — |
| Galera Therapeutics, Inc. GRTX | FY2025 | N/A | N/A | N/A | $6.5M | — |
| Ayala Pharm ADXS | FY2023 | $13K | -$48.1M | N/A | $25.7M | — |
Where Axim Biotechnologies Inc Ranks
Frequently Asked Questions
What is Axim Biotechnologies Inc's annual revenue?
Axim Biotechnologies Inc (AXIM) reported $40K in total revenue for fiscal year 2023. This represents a 345.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Axim Biotechnologies Inc's revenue growing?
Axim Biotechnologies Inc (AXIM) revenue grew by 345.3% year-over-year, from $9K to $40K in fiscal year 2023.
Is Axim Biotechnologies Inc profitable?
No, Axim Biotechnologies Inc (AXIM) reported a net income of -$8.1M in fiscal year 2023.
What is Axim Biotechnologies Inc's EBITDA?
Axim Biotechnologies Inc (AXIM) had EBITDA of -$2.3M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Axim Biotechnologies Inc have?
As of fiscal year 2023, Axim Biotechnologies Inc (AXIM) had $156K in cash and equivalents against $137K in long-term debt.
What is Axim Biotechnologies Inc's free cash flow?
Axim Biotechnologies Inc (AXIM) recorded an outflow of $1.0M in free cash flow during fiscal year 2023. This represents a 49.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Axim Biotechnologies Inc's operating cash flow?
Axim Biotechnologies Inc (AXIM) recorded an outflow of $1.0M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are Axim Biotechnologies Inc's total assets?
Axim Biotechnologies Inc (AXIM) had $4.1M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Axim Biotechnologies Inc's capital expenditures?
Axim Biotechnologies Inc (AXIM) reported no capital expenditure during fiscal year 2023.
How much does Axim Biotechnologies Inc spend on research and development?
Axim Biotechnologies Inc (AXIM) invested $125K in research and development during fiscal year 2023.
What is Axim Biotechnologies Inc's current ratio?
Axim Biotechnologies Inc (AXIM) had a current ratio of 0.03 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Axim Biotechnologies Inc's return on assets (ROA)?
Axim Biotechnologies Inc (AXIM) had a return on assets of -195.6% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Axim Biotechnologies Inc's P/E ratio?
Axim Biotechnologies Inc (AXIM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2024). The market capitalization is $1.3M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Axim Biotechnologies Inc's price-to-sales ratio?
Axim Biotechnologies Inc (AXIM) trades at 14.4x sales, its market capitalization divided by revenue of $93K revenue, trailing 12 months to June 30, 2024. The market capitalization is $1.3M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Axim Biotechnologies Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, Axim Biotechnologies Inc (AXIM) held $156K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.0M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Axim Biotechnologies Inc's debt-to-equity ratio negative or not reported?
Axim Biotechnologies Inc (AXIM) has negative shareholder equity of -$7.7M as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Axim Biotechnologies Inc's Altman Z-Score?
Axim Biotechnologies Inc (AXIM) has an Altman Z-Score of -28.34, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Axim Biotechnologies Inc's Piotroski F-Score?
Axim Biotechnologies Inc (AXIM) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Axim Biotechnologies Inc's earnings high quality?
Axim Biotechnologies Inc (AXIM) reported a net loss of $8.1M while operations used $1.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Axim Biotechnologies Inc cover its interest payments?
Axim Biotechnologies Inc (AXIM) reported an operating loss of $2.8M against $140K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.